Absolute bioavailability and pharmacokinetics of medifoxamine in healthy humans.
Medifoxamine is a new monoamine re-uptake inhibiting antidepressant drug. Twelve volunteers received 100 mg by i.v. infusion over 15 min and 500 mg by mouth fasting. The treatments were given 1 week apart in a randomised cross-over design. Venous blood samples (10 ml) were taken at intervals for 24 h for h.p.l.c. measurement of serum medifoxamine. A biexponential decline of serum medifoxamine concentration was observed after intravenous administration in all subjects and similar terminal elimination half-lives were observed following both routes, indicating that oral absorption is not rate-limiting. The absolute bioavailability of oral medifoxamine was 21%.
Saleh
S
S
Department of Clinical Pharmacology, St Bartholomew's Hospital, London.
Johnston
A
A
Turner
P
P
D000328:Adult; D000928:Antidepressive Agents / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine; D001682:Biological Availability; D005021:Ethylamines / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine; D005260:Female; D006207:Half-Life; D006801:Humans; D008297:Male; D012016:Reference Values
D000928:Antidepressive Agents; D005021:Ethylamines; C034065:medifoxamine